Anika Therapeutics | ANIK - Operating Expenses


Anika Therapeutics reported $137.28M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Abbott USD 10.46B 1.15B Jun/2026
Agenus USD -199.08M 22.15M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 526.79M 20.55M Jun/2026
Integra LifeSciences USD 1.04B 971K Jun/2026
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 18.93B 1.09B Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 55.1M 20.75M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merit Medical Systems USD 358.44M 20.72M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.92B 607M Jun/2026
Smith & Nephew USD 2.59B 71M Jun/2026
Stryker USD 4.8B 118M Jun/2026
Veracyte USD 126.36M 6.37M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026
Zimmer Biomet Holdings USD 1.83B 140.7M Jun/2026